You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023234018
Dec 202382012
Jan 202469015
Feb 20247408
Mar 202452013
Apr 20246609
May 202444010
Jun 20244004
Jul 20243009
Aug 20242803
Sep 20243003
Oct 202428012
Nov 20244007
Dec 20245206
Jan 20252804
Feb 2025403
Mar 2025005
Apr 2025103
May 2025007
Jun 2025002
Total9020153